Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects

Journal of Clinical Oncology

Volumn 18, Issue 10, 2000, Pages 2104-2115

  de Jonge, Maja J A ^a   Loos, Walter J ^a   Gelderblom, Hans ^a   Planting, André S Th ^a   van der Burg, Maria E L ^a   Sparreboom, Alex ^a   Brouwer, Eric ^a   van Beurden, Vera ^a   Mantel, Marijke A ^a   Doyle, Eddie ^a   Hearn, Solange ^a   Ross, Graham ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 17144433130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.10.2104     Document Type: Article

References (52)

1. Hsiang Y-H, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
2. Eng W-K, Faucette L, Johnson RK, et al: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988
3. Hsiang Y-H, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
4. De Jonge MJA, Sparreboom A, Verweij J: The development of combination therapy involving camptothecins: A review of preclinical and early clinical studies. Cancer Treat Rev 24:205-220, 1998
5. Ma J, Maliepaard M, Nooter K, et al: Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41:307-316, 1998
6. Maliepaard M, van Klink Y, Floot BJG, et al: Schedule-dependent cytotoxicity of topotecan or SN-38 and platinum (II) and (IV) compounds in vitro. Presented at the 8th Conf DNA Topoisomerase, Amsterdam, the Netherlands, October 15-17, 1997 (abstr 92)
7. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cisdiaminodichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous carcinoma cells. Int J Cancer 62:70-75, 1995
8. Kano Y, Suzuki K, Akutsu M, et al: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604-610, 1992
9. Romanelli S, Perego P, Pratesi G, et al: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41:385-390, 1998
10. Chou T-C, Motzer RJ, Tong Y, et al: Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
11. Blay J, Poon A, Skillings JR, et al: Cytotoxicity of topotecan with cisplatin or etoposide (VP-16) on lung, breast and colon carcinoma cells in vitro. Can J Physiol Pharmacol 72:198, 1994 (abstr P2.2.15)
12. Jensen PB, Holm B, Sorensen M, et al: In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to Taxotere, Taxol, topotecan and gemcitabine. Br J Cancer 75:869-877, 1997
13. Waud WR, Rubinstein LV, Kalyandrug S, et al: In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide. Proc Am Assoc Cancer Res 37:292, 1996 (abstr 1988)
14. Kaufmann SC, Peereboom D, Buckwalter CA, et al: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741, 1996
15. Keane TE, El-Galley RE, Sun C, et al: Camptothecin analogues/ cisplatin: An effective treatment of advanced bladder cancer in a preclinical in vivo model system. J Urol 160:252-256, 1998
16. Takiyama I, Terashima M, Ikeda K, et al: Remarkable synergistic interaction between camptothecin analogs and cisplatin against human esophageal cancer cell lines. Proc Am Assoc Cancer Res 38:15, 1997 (abstr 101)
17. Rowinsky EK, Kaufmann SH, Baker SD, et al: Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-3084, 1996
18. Kudelka AP, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
19. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
20. Hoskins P, Eisenhauer E, Beare S, et al: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16:2233-2237, 1998
21. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
22. Bookman MA, Malmström H, Bolis G, et al: Topotecan for the treatment of advanced ovarian cancer: An open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352, 1998
23. Swisher EM, Mutch DG, Rader JS, et al: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66:480-486, 1997
24. Schiller JH, Kim K-M, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
25. Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785-2790, 1996
26. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997
27. Rowinsky EK, Adjie AA, Donehower RC, et al: A phase I and pharmacodynamic study of topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994
28. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed leukemia. Blood 81:1146-1151, 1993
29. Beran M, Kantarjian H: Topotecan in the treatment of hematologic malignancies. Semin Hematol 35:26-31, 1998
30. Beran M, Kantarjian HM, Keating M, et al: Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Blood 90, 1997 (suppl 1, abstr 2593)
31. Kuhn J, Rizzo J, Eckardt J, et al: Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 14:474a, 1995 (abstr 1538)
32. Schellens JHM, Creemers GJ, Beijnen JH, et al: Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor. Br J Cancer 73:1268-1271, 1996
33. Herben VMM, Rosing H, ten Bokkel Huinink WW, et al: Oral topotecan: Bioavailability and effect of food co-administration. Br J Cancer 80:1380-1386, 1999
34. Gerrits CJH, Burns H, Schellens JHM, et al: Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 34:1030-1035, 1998
35. Gore M, Rustin G, Calvert H, et al: A multicenter, randomized, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 17:349a, 1998 (abstr 1346)
36. Von Pawel J, Gatzemeier U, Harstrick A, et al: A multicenter randomized phase II study of oral topotecan versus iv topotecan for second line therapy in sensitive patients with small cell lung cancer. Proc Am Soc Clin Oncol 18:471a, 1999 (abstr 1816)
37. Loos WJ, Stoter G, Verweij J, et al: Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. J Chromatogr B Biomed Appl 678:309-315, 1996
38. Ma J, Verweij J, Planting AST, et al: Current sample handling methods for measurement of platinum-DNA adducts in leukocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer 71:512-517, 1995
39. Ma J, Stoter G, Verweij J, et al: Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 38:391-394, 1996
40. Reed E, Sauerhoff S, Poirier MC: Quantitation of platinum-DNA binding after therapeutic levels of drug exposure: A novel use of graphite furnace spectrometry. Atomic Spectrom 9:93-95, 1988
41. Ma J, Verweij J, Kolker HJ, et al: Pharmacokinetic-dynamic relationship of cisplatin in vitro: Simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer 69:858-862, 1994
42. Schellens JHM, Ma J, Planting AST, et al: Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumour response in patients with solid tumours. Br J Cancer 73:1569-1575, 1996
43. Cheng M-F, Chatterjee S, Berger NA: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269-279, 1994
44. Miller AA, Hargis JB, Lilenbaum RC, et al: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 12:2743-2750, 1994
45. Sorensen M, Jensen PB, Sehested M, et al: Phase I/II study of topotecan and cisplatin alternating with carboplatin, cisplatin, teniposide and vincristine in previously untreated patients with small-cell lung cancer. Proc Am Soc Clin Oncol 17:501a, 1998 (abstr 1931)
46. van Warmerdam LJC, Verweij J, Schellens JHM, et al: Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 35:237-245, 1995
47. van Warmerdam LJC, Creemers GJ, Rodenhuis S, et al: Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol 38:254-260, 1996
48. Goldwasser F, Bozec L, Zeghari-Squalli N, et al: Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs 10:195-201, 1999
49. Goldwasser F, Valenti M, Torres R, et al: Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 2:687-693, 1996
50. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5:1189-1196, 1999
51. Maliepaard M, van Klink YCF, Ruiz van Haperen VWT, et al: Topoisomerase I protein level involved in schedule-dependent cytotoxicity of topotecan (TPT) or SN-38 and platinum (II) and (IV) drugs in vitro. Proc Am Assoc Cancer Res 40:108, 1999 (abstr 721)
52. Fukuda M, Nishio K, Kanzawa F, et al: Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56:789-793, 1996